ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY24 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) updated its FY24 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $4.90-5.05 for the period, compared to the consensus estimate of $4.72. The company issued revenue guidance of $594-602 million, compared to the consensus revenue estimate of $590.33 million. ANI Pharmaceuticals also updated its FY 2024 guidance to 4.900-5.050 EPS.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. HC Wainwright restated a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an "overweight" rating and a $68.00 price target for the company. Truist Financial upped their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research report on Tuesday, October 22nd. Raymond James upped their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 18th. Finally, StockNews.com cut shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $77.33.

ANI Pharmaceuticals Trading Down 0.0 %

NASDAQ ANIP opened at $58.38 on Friday. The company has a fifty day simple moving average of $58.70 and a two-hundred day simple moving average of $61.58. The stock has a market cap of $1.23 billion, a P/E ratio of 49.90 and a beta of 0.71. ANI Pharmaceuticals has a 12-month low of $48.20 and a 12-month high of $70.81. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.95 by $0.07. The firm had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The business's quarterly revenue was up 18.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.06 earnings per share. On average, analysts forecast that ANI Pharmaceuticals will post 3.5 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.